David Lewis – CEO
David has a strong history of delivery within the global medical technology space, having started his career with Johnson & Johnson and CR Bard. David then spent 15 years at Medtronic, holding progressive Senior Leadership roles, which culminated in heading up the Cardiovascular Group of businesses across the Asia Pacific region.
More recently, he was VP International at Endologix Inc. and has also spent several years consulting to early-stage companies, including Veryan Medical, leading on establishing market presence and new product launches across international geographies.
David has operated as a commercial leader at the most senior level in these market-leading companies, and he joins Ablatus at a particularly exciting time, following the recent award of a significant £1.42 m Innovate UK grant, and with the company enjoying strong investor support for its pathway to CE mark and commercial availability of the first BETA liver tumour ablation system.
Natalie Hayes – Chief Medical Officer
Natalie qualified with Honours in Medicine in 2000, having obtained an intercalated First Class Honours Bachelor of Science degree in 1999. She obtained a Doctorate of Medicine for research in transplantation and immunosuppressive therapy in 2006.
She worked in the NHS in the UK surgery and radiology for 6 years, before being appointed as medico-legal adviser with the major medical defence organisation in the UK, where she worked for a further 9 years, progressing to hold a number of senior roles. She obtained a Graduate Diploma in Law with Commendation in 2008 and completed the Legal Practice Course with Distinction in 2010.
She is a Member of the Faculty of Forensic and Legal Medicine and served as Examiner for the Faculty examinations and was Chair of the Academic Committee until 2015.
More recently, she was Director of Clinical and Regulatory Affairs for a University of Cambridge medical technology start-up company, and Global Medical Director for a Canadian wound care and medical technology company. She has also provided consultancy services to a number of other healthcare organizations and medical device and technology companies.
Tracey Morton, Chief Financial Officer
Tracey is a Fellow of the Chartered Institute of Management Accountants and has a Masters Degree in Business Law.
She brings a wealth of leadership experience in Life Science and FCMG sectors – her most recent roles include one as CFO for an Oxford University spin off Bio-tech diagnostics company, where as part of a successful team, she participated in a $60 Million fundraising project in both the US and UK.
The Board are delighted to have someone of Tracey’s calibre join the company and believe the breadth and operational experience, across multiple functional responsibilities, will be a huge benefit to us at this exciting time.
Bill Allan – Chairman
Bill is an internationally- experienced medical devices executive who has held a number of general management and leadership positions with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker.
He has a strong track record of building businesses and launching new products and has worked in Europe, Africa and North America.
Educated at the University of Edinburgh, University of Capetown and Insead Business School, Bill is a mentor at Cambridge University (Judge) Business School and a council member of ABHI (Association of British Healthcare Industries).
Anne Blackwood – Non-Executive Director
Dr Anne Blackwood is currently Chief Executive of Health Enterprise East, a leading NHS Innovation Hub and Technology Consultancy.
Anne has been actively involved in knowledge transfer and intellectual property management in the life sciences for over 15 years.
Since becoming Chief Executive at HEE, Anne has successfully transformed the organisation into a professional services company with a wide range of public and private sector clients.
Anne is also a Director of the Health Innovations Alliance which represents the body of NHS Innovation Hubs nationally.
Prior to joining HEE, Anne spent 4 years with Cambridge Enterprise, the Technology Transfer arm of the University of Cambridge. Anne holds a PhD in chemistry from Strathclyde University.
Professor Marcus Flather – Non-Executive Director
Marcus Flather graduated from the Royal Free Hospital School of Medicine, University of London in 1982 and trained in general medicine and cardiology in London and Oxford.
In 1993 he moved to McMaster University in Hamilton, Canada until 1996 when he took up the post of Director of the new Clinical Trials and Evaluation Unit (CTEU) at the Royal Brompton and Harefield Hospitals.
In September 2011 he took up the post of Professor of Medicine and Clinical Trials at the University of East Anglia and Director of Research at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich.
Marcus Flather is a Fellow of the Royal College of Physicians (UK) and holds a certificate of higher specialist training in Cardiology and General (Internal) Medicine in the UK (CCST). He has about 200 peer reviewed publications, is a recognised expert in clinical trials and has more than 20 years experience of collaborating with industry partners in drug and device development.